ValiRx plc Share Price

VAL

GB00BLH13C52

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:22 10/07/2026 pm IST			5-day change	1st Jan Change
0.1450 ^GBX	-3.33%		-9.38%	-56.72%

23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows	AN
22/06	Maintel fundraising completes; ValiRx ends deal	AN

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	GBX 0.1450	-3.33%	12,73,65,636
09/26/09	GBX 0.1500	-3.23%	1,96,00,569
08/26/08	GBX 0.1550	0.00%	2,265
07/26/07	GBX 0.1550	0.00%	4,602
06/26/06	GBX 0.1550	-3.13%	31,54,434

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	11.13L 14.89L 13.06L 12.06L 21.09L 14Cr 21.47L 1.44Cr 56.24L 6.95Cr 55.9L 54.72L 24Cr	P/E 2024	-0.53x	P/E 2025	-0.62x
Enterprise Value	3L 4L 4L 3L 6L 4.12Cr 6L 41.82L 16.32L 2.02Cr 16.22L 15.88L 7Cr	EV / Sales 2024	2,72,64,249x	EV / Sales 2025	5,41,21,446x
Free-Float	93.4%	Yield 2024 *	-	Yield 2025	-

23/06	EARNINGS AND TRADING: ValiRx profit slides; Ukrproduct loss narrows	AN
22/06	Maintel fundraising completes; ValiRx ends deal	AN
22/06	Valirx plc Announces the Resignation of Tralau-Stewart as Chair of the Advisory Board	CI
22/06	ValiRx plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/06	Earnings Flash (VAL.L) ValiRx Plc Reports FY25 Revenue GBP31,372	MT
02/06	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
28/05	ValiRx subsidiary Cytolytix granted "core" European patent	AN
27/05	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent	MT
21/05	ValiRx Raises Funds via Retail Offering	MT
18/05	ValiRx to Raise Funds via Retail Offer	MT
15/05	IAG launches new buyback; Forgent settles legal case	AN
15/05	WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach	AN
15/05	ValiRx Seeks to Raise Over GBP1 Million via Share Issue	MT

24/25/24	ValiRx PLC - Director Disclosure Update	AQ
19/24/19	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/23/06	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/23/01	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/22/16	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ

1 day	-3.33%
1 week	-9.38%
Current month	-9.38%
1 month	-23.68%
3 months	-53.23%
6 months	-62.82%
Current year	-56.72%

1 week	0.13	0.17
1 month	0.13	0.19
Current year	0.13	0.48
1 year	0.13	0.85
3 years	0.13	15
5 years	0.13	65
10 years	0.13	1,436.25

ValiRx plc Share Price

Stocks

VAL

GB00BLH13C52

Biotechnology & Medical Research

Valuation: ValiRx plc

Chart: ValiRx plc

Latest news : ValiRx plc

Press Releases: ValiRx plc

Quotes and Performance

Course Extremes

Managers and Directors: ValiRx plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Manager	Title	Age	Since
Mark Eccleston CEO	Chief Executive Officer	55	12/08/2024
Gerald Desler DFI	Director of Finance/CFO	81	-
Michelle Barnard CTO	Chief Tech/Sci/R&D Officer	-	27/03/2025

Director	Title	Age	Since
Gerald Desler BRD	Director/Board Member	81	01/09/2006
Martin Gouldstone CHM	Chairman	59	25/07/2024
Mark Eccleston BRD	Director/Board Member	55	12/08/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/03	Mark Eccleston	Buy	Chief Executive Officer	10,00,000	0.1346%
18/22/18	Stella Panu	Free	Director	75,000	0.0832%
18/22/18	Stella Panu	Free	Director	75,000	0.0832%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALIRX PLC	-3.33%	-9.38%	-75.83%	-97.91%	14.94L
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+59.82%	+92.96%	5.49TCr
ARGENX SE	-4.14%	-8.06%	+58.96%	+118.67%	5.46TCr
INSMED INCORPORATED	-2.24%	+3.59%	+17.75%	+477.47%	2.51TCr
BIONTECH SE	-1.60%	-6.21%	-18.96%	-15.21%	2.31TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+42.44%	-1.27%	1.99TCr
GENMAB A/S	-3.19%	0.00%	+35.60%	-26.98%	1.75TCr
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	1.65TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+51.91%	+726.40%	1.57TCr
EXELIXIS, INC.	-1.05%	+1.16%	+25.95%	+194.27%	1.42TCr
Average	-0.94%	-1.19%	+39.28%	+182.56%	2.42TCr
Weighted average by Cap.	-0.90%	-1.45%	+51.26%	+177.13%

	2024	2025
Net sales	0.05 0.07 0.06 0.05 0.09 6.35 0.1 0.64 0.25 3.11 0.25 0.24 10.79	0.03 0.04 0.04 0.03 0.06 4 0.06 0.41 0.16 1.96 0.16 0.15 6.8
Net income	-19.16L -25.62L -22.48L -20.75L -36.3L -24Cr -36.94L -2.48Cr -96.78L -12Cr -96.19L -94.15L -42Cr	-22.32L -29.86L -26.19L -24.18L -42.29L -28Cr -43.04L -2.89Cr -1.13Cr -14Cr -1.12Cr -1.1Cr -48Cr
Net Debt	-15.44L -20.65L -18.12L -16.73L -29.26L -20Cr -29.78L -2Cr -78.01L -9.64Cr -77.53L -75.89L -33Cr	-8L -10.57L -9L -9L -14.97L -10Cr -15.24L -1.02Cr -39.92L -4.93Cr -39.68L -38.84L -17Cr